Confronto

GHRP-2 vs. Ipamorelin

Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.

Identità

Categoria

Crescita

N. CAS

158861-67-7

170851-70-4

Peso molecolare

817.93 g/mol

711.86 g/mol

Emivita

0.5 h

2 h

Sequenza

D-Ala-D-2-Naphthyl-Ala-Ala-Trp-D-Phe-Lys-NH2

Aib-His-D-2-Nal-D-Phe-Lys-NH2

Meccanismo d'azione

GHRP-2

GHRP-2 binds with high affinity to the GH secretagogue receptor (GHSR-1a) in the pituitary and hypothalamus. Activation leads to rapid release of pulsatile growth hormone. Unlike GHRH, GHRP-2 acts via a separate pathway and can be combined synergistically with GHRH to elicit maximal GH responses in provocation tests.

Ipamorelin

Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.

Base di evidenze

Evidenza più alta

Studio sull'uomo

RCT sull'uomo

Studi

di cui sull'uomo

Effetti registrati

Contraddizioni aperte

Eventi avversi documentati

Stato legale

Country	GHRP-2	Ipamorelin
Germania	Non approvato	Non approvato
JP	Su prescrizione	—
Stati Uniti	Non approvato	Non approvato

Voci complete

Frequently asked questions

What is the difference between GHRP-2 and Ipamorelin?: GHRP-2 is classified as "Crescita", while Ipamorelin is classified as "Crescita". GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, GHRP-2 or Ipamorelin?: The highest available evidence level is "Studio sull'uomo" for GHRP-2 and "RCT sull'uomo" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of GHRP-2 and Ipamorelin in Germany and the United States?: Germania: GHRP-2 — Non approvato, Ipamorelin — Non approvato. Stati Uniti: GHRP-2 — Non approvato, Ipamorelin — Non approvato. These are factual summaries with source and review date on the individual pages.

Country

GHRP-2

Ipamorelin

Germania

Non approvato

Su prescrizione

—

Stati Uniti

Non approvato

Frequently asked questions

What is the difference between GHRP-2 and Ipamorelin?

GHRP-2 is classified as "Crescita", while Ipamorelin is classified as "Crescita". GHRP-2: Synthetic hexapeptide of the GH secretagogue family. Approved in Japan as GHRP Kaken as a diagnostic test for GH deficiency. Not available as a medicine outside Japan. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, GHRP-2 or Ipamorelin?

The highest available evidence level is "Studio sull'uomo" for GHRP-2 and "RCT sull'uomo" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of GHRP-2 and Ipamorelin in Germany and the United States?

Germania: GHRP-2 — Non approvato, Ipamorelin — Non approvato. Stati Uniti: GHRP-2 — Non approvato, Ipamorelin — Non approvato. These are factual summaries with source and review date on the individual pages.